NeoTract, Inc.'s Minimally Invasive UroLift System For Enlarged Prostate Now Shown To Be Durable Through Five Years: Results From Pivotal L.I.F.T. Randomized Study Presented Post author:Sam Post published:March 26, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017 Bio-Rad Release: Company To Report Fourth-Quarter And Full-Year 2016 Financial Results Thursday, February 23, 2017 January 18, 2017 Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017
Bio-Rad Release: Company To Report Fourth-Quarter And Full-Year 2016 Financial Results Thursday, February 23, 2017 January 18, 2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017